Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons dr. T.J.N. Hiltermann

Publicaties

Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis

Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis

Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab

Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2)

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Sex-based differences in effectiveness of immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer: systematic review and meta-analysis

Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors-An Explorative Study

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Pers/media

Neo- en perioperatieve chemo-immunotherapie bij NSCLC

TLCR Outstanding Author interview

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

Terminaal zieke John Franke strijdt met podcast voor bevolkingsonderzoek naar longkanker

Primeur met TCR T-cellen

EERSTE LONGKANKERPATIËNT BEHANDELD MET GEMODIFICEERDE T-CELLEN Primeur met TCR T-cellen

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijnSDG 9 – Industrie, innovatie en infrastructuur

Meer informatie over de Sustainable Development Goals.